HC Wainwright Expects Lower Earnings for ProQR Therapeutics

Key Points

• HC Wainwright lowered ProQR Therapeutics’ Q3 2026 EPS estimate to a loss of $0.10 from $0.09, while maintaining a “Buy” rating. Its full-year 2026 and 2027 estimates are both losses of $0.43 per share.
• ProQR recently exceeded quarterly expectations, reporting a $0.09 per-share loss versus the $0.13 consensus loss and revenue of $10.0 million versus the $4.56 million estimate.
• Despite mixed analyst actions, the stock has a “Moderate Buy” consensus rating and a $7.33 target price. Insiders purchased 600,000 shares worth approximately $988,500 over the past 90 days.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Stock analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Monday, August 17th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will earn ($0.10) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for ProQR Therapeutics' Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.43) EPS and FY2027 earnings at ($0.43) EPS.

Other equities analysts have also recently issued research reports about the stock. Chardan Capital dropped their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, June 26th. Wall Street Zen raised ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Saturday. Citigroup reiterated a "market outperform" rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. JonesTrading reduced their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, June 26th. Finally, Weiss Ratings upgraded ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, ProQR Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.33.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $2.15 on Wednesday. ProQR Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.10. The firm's 50-day simple moving average is $1.76 and its 200 day simple moving average is $1.66. The stock has a market cap of $226.52 million, a PE ratio of -4.67 and a beta of 0.07.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%.

Insider Transactions at ProQR Therapeutics

In other ProQR Therapeutics news, CEO Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock in a transaction dated Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares of the company's stock, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bart Filius purchased 150,000 shares of the company's stock in a transaction that occurred on Friday, July 17th. The shares were acquired at an average price of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the purchase, the director directly owned 300,000 shares in the company, valued at $516,000. This represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 600,000 shares of company stock worth $988,500 over the last 90 days. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its holdings in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 4,500 shares during the period. Guggenheim Capital LLC purchased a new stake in ProQR Therapeutics during the 4th quarter worth about $35,000. Invesco Ltd. bought a new position in ProQR Therapeutics in the 4th quarter worth about $51,000. Axiom Investment Management LLC bought a new position in ProQR Therapeutics in the 1st quarter worth about $53,000. Finally, Simplex Trading LLC grew its holdings in ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company's stock valued at $89,000 after buying an additional 44,169 shares in the last quarter. Institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source